论文部分内容阅读
由上海第十二制药厂研制的抗肿瘤药氨格鲁米特(aminoglutethem-ide,AG)已在1986年12月10日通过鉴定。鉴定会由上海市医药管理局主持召开。由李云月教授等7人组成鉴定委员会。会上,由上海第十二制药厂AG研制负责人黄恺工程师等介绍AG的作用原理、工艺路线、释放度和稳定性、质量标准等。然后由上海医科大学附属肿瘤医院等8家医疗单位的专家介绍治疗晚期乳腺癌的临床试用情况。上海瑞金医院的代表还介绍以往用AG治疗柯兴综合征的经验。经与会代表认真讨论后,一致通过了鉴定。AG临床协作组治疗晚期转移性乳腺癌共133例,对照组他莫昔芬(tamoxifen,
The antitumor drug aminoglutethymide (AG) developed by the 12th Shanghai Pharmaceutical Factory was approved on December 10, 1986. Identification will be chaired by the Shanghai Medical Administration. By Professor Li Yunyue seven other members of the identification committee. At the meeting, Dr. Zhang Kai, the head of AG development at Shanghai No. 12 Pharmaceutical Factory, introduced the working principle, process route, release degree and stability of AG, and quality standards. Then by the Shanghai Medical University Affiliated Tumor Hospital and other eight medical experts introduced clinical trial of advanced breast cancer. Representatives from Shanghai Ruijin Hospital also introduced the past experience of treating Cushing’s syndrome with AG. After careful discussion by the delegates, unanimously passed the appraisal. AG clinical cooperation group for the treatment of advanced metastatic breast cancer a total of 133 cases of the control group tamoxifen (tamoxifen,